BioNTech SE (BNTX) 10-Year Financial Performance & Capital Metrics

BNTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutBioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.Show more

Revenue $2.75B -28.0%
EBITDA -$1.02B -216.3%
Net Income -$665M -171.5%
EPS (Diluted) -2.77 -172.3%
Gross Margin 80.32% -4.7%
EBITDA Margin -36.94% -261.5%
Operating Margin -47.77% -364.3%
Net Margin -24.18% -199.3%
ROE -3.36% -172.7%
ROIC -10.54% -254.6%
Debt/Equity 0.01 +21.0%
Interest Coverage -99.86 -212.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Excellent 3Y average ROE of 20.1%
✓Strong 5Y sales CAGR of 90.9%
✓Healthy 5Y average net margin of 22.4%
✓Trading at only 1.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y90.87%

3Y-47.47%

TTM3.7%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-22.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM-13.94%

ROCE

10Y Avg26.41%

5Y Avg56.95%

3Y Avg24.77%

Latest-6.42%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	61.6M	127.58M	108.6M	482.3M	18.98B	17.31B	3.82B	2.75B
Revenue Growth %	-	1.07%	-0.15%	3.44%	38.35%	-0.09%	-0.78%	-0.28%
Cost of Goods Sold+	9.32M	13.69M	17.4M	59.3M	2.91B	3B	599.8M	541.3M
COGS % of Revenue	0.15%	0.11%	0.16%	0.12%	0.15%	0.17%	0.16%	0.2%
Gross Profit+	52.28M	113.89M	91.2M	423M	16.07B	14.32B	3.22B	2.21B
Gross Margin %	0.85%	0.89%	0.84%	0.88%	0.85%	0.83%	0.84%	0.8%
Gross Profit Growth %	-	1.18%	-0.2%	3.64%	36.98%	-0.11%	-0.78%	-0.31%
Operating Expenses+	113.56M	167.74M	272.7M	505.4M	781.4M	1.67B	2.53B	3.52B
OpEx % of Revenue	1.84%	1.31%	2.51%	1.05%	0.04%	0.1%	0.66%	1.28%
Selling, General & Admin	29.49M	27.07M	43.3M	108.5M	327.2M	541.2M	557.7M	599M
SG&A % of Revenue	0.48%	0.21%	0.4%	0.22%	0.02%	0.03%	0.15%	0.22%
Research & Development	85.5M	143.07M	226.5M	645M	949.2M	1.54B	1.78B	2.25B
R&D % of Revenue	1.39%	1.12%	2.09%	1.34%	0.05%	0.09%	0.47%	0.82%
Other Operating Expenses	-1.43M	-2.39M	2.9M	-248.1M	-495M	-405.3M	188M	670.9M
Operating Income+	-61.28M	-53.85M	-181.5M	-82.4M	15.28B	12.64B	690.4M	-1.31B
Operating Margin %	-0.99%	-0.42%	-1.67%	-0.17%	0.81%	0.73%	0.18%	-0.48%
Operating Income Growth %	-	0.12%	-2.37%	0.55%	186.48%	-0.17%	-0.95%	-2.9%
EBITDA+	-50.75M	-31.87M	-147.6M	-43.7M	15.36B	12.77B	873.8M	-1.02B
EBITDA Margin %	-0.82%	-0.25%	-1.36%	-0.09%	0.81%	0.74%	0.23%	-0.37%
EBITDA Growth %	-	0.37%	-3.63%	0.7%	352.46%	-0.17%	-0.93%	-2.16%
D&A (Non-Cash Add-back)	10.53M	21.98M	33.9M	38.7M	75.2M	123.3M	183.4M	298M
EBIT	-85.23M	-45.94M	-177.7M	-143.8M	14.93B	12.97B	1.19B	-665.1M
Net Interest Income+	1.4M	284.04K	62.1K	-408.5K	-4.07M	31.55M	343.55M	-13.16M
Interest Income	2.06M	2.06M	1.76M	1.46M	1.56M	47.37M	351.31M	0
Interest Expense	651.44K	1.78M	1.69M	1.86M	5.63M	15.82M	7.76M	13.16M
Other Income/Expense	-24.63M	6.19M	2.1M	-63.4M	-237.4M	311.4M	495.7M	636.6M
Pretax Income+	-85.91M	-47.66M	-179.4M	-145.8M	15.05B	12.95B	1.19B	-677.7M
Pretax Margin %	-1.39%	-0.37%	-1.65%	-0.3%	0.79%	0.75%	0.31%	-0.25%
Income Tax+	45K	600K	-200K	-161M	4.75B	3.52B	255.8M	-12.4M
Effective Tax Rate %	1%	1.01%	1%	-0.1%	0.68%	0.73%	0.78%	0.98%
Net Income+	-85.65M	-48.02M	-179.1M	15.2M	10.29B	9.43B	930.3M	-665.3M
Net Margin %	-1.39%	-0.38%	-1.65%	0.03%	0.54%	0.55%	0.24%	-0.24%
Net Income Growth %	-	0.44%	-2.73%	1.08%	676.14%	-0.08%	-0.9%	-1.72%
Net Income (Continuing)	-85.95M	-48.26M	-179.2M	15.2M	10.29B	9.43B	930.3M	-665.3M
Discontinued Operations	91.29K	0	0	0	0	0	0	0
Minority Interest	1.09M	847K	0	0	0	0	0	0
EPS (Diluted)+	-0.38	-0.21	-0.85	0.06	41.21	37.09	3.83	-2.77
EPS Growth %	-	0.45%	-3.05%	1.07%	721.98%	-0.1%	-0.9%	-1.72%
EPS (Basic)	-0.38	-0.21	-0.85	0.06	43.87	38.08	3.87	-2.77
Diluted Shares Outstanding	226.86M	226.86M	211.5M	248.53M	259.7M	249.8M	242.7M	240.4M
Basic Shares Outstanding	226.86M	226.86M	211.5M	235.44M	244M	243.3M	240.6M	240.4M
Dividend Payout Ratio	-	-	-	-	-	0.05%	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	189.64M	448.96M	560.15M	1.67B	15.07B	21.92B	19.53B	18.8B
Cash & Short-Term Investments	172.35M	411.83M	520.83M	1.35B	2.07B	14.06B	16.55B	16.78B
Cash Only	172.11M	411.5M	519.15M	1.21B	1.69B	13.88B	11.66B	9.76B
Short-Term Investments	246K	336K	1.68M	137.2M	381.6M	189.4M	4.89B	7.02B
Accounts Receivable	4.58M	28.44M	11.91M	165.5M	12.38B	7.15B	2.34B	1.52B
Days Sales Outstanding	27.11	81.37	40.04	125.25	238.16	150.68	223.62	202.18
Inventory	3.88M	5.79M	12.07M	64.1M	502.5M	439.6M	357.7M	283.3M
Days Inventory Outstanding	151.83	154.35	253.26	394.54	63	53.57	217.67	191.03
Other Current Assets	8.83M	12.25M	15.34M	89.9M	113.4M	271.9M	280.9M	212.7M
Total Non-Current Assets+	185.08M	204.03M	237.5M	651.7M	758.5M	1.36B	3.48B	3.73B
Property, Plant & Equipment	101.52M	115.97M	148.06M	326M	520.4M	821.1M	971.6M	1.18B
Fixed Asset Turnover	0.61x	1.10x	0.73x	1.48x	36.47x	21.08x	3.93x	2.32x
Goodwill	534K	534K	2.98M	53.7M	57.8M	61.2M	362.5M	380.6M
Intangible Assets	83M	87.51M	84.05M	103.8M	144.6M	158.5M	804.1M	790.4M
Long-Term Investments	19K	18K	0	0	21.3M	80.2M	1.18B	1.25B
Other Non-Current Assets	-2K	-1K	2.4M	168.2M	14.4M	6.5M	83.4M	36.1M
Total Assets+	374.71M	652.99M	797.65M	2.32B	15.83B	23.28B	23.01B	22.53B
Asset Turnover	0.16x	0.20x	0.14x	0.21x	1.20x	0.74x	0.17x	0.12x
Asset Growth %	-	0.74%	0.22%	1.91%	5.83%	0.47%	-0.01%	-0.02%
Total Current Liabilities+	158.54M	126.12M	138.14M	606M	3.48B	2.95B	2.07B	2.52B
Accounts Payable	52.54M	41.72M	20.5M	102.3M	160M	204.1M	354M	426.7M
Days Payables Outstanding	2.06K	1.11K	429.99	629.67	20.06	24.87	215.42	287.72
Short-Term Debt	0	0	1.82M	3M	129.9M	36M	28.1M	39.5M
Deferred Revenue (Current)	1000K	1000K	0	0	1000K	1000K	1000K	1000K
Other Current Liabilities	86.73M	79.16M	105.63M	494.6M	1.44B	2.04B	809.6M	1.76B
Current Ratio	1.20x	3.56x	4.05x	2.75x	4.33x	7.43x	9.43x	7.45x
Quick Ratio	1.17x	3.51x	3.97x	2.64x	4.18x	7.28x	9.26x	7.34x
Cash Conversion Cycle	-1.88K	-876.64	-136.69	-109.88	281.1	179.38	225.87	105.49
Total Non-Current Liabilities+	264.38M	259.87M	166.01M	340.8M	455.5M	272.9M	689.9M	595.4M
Long-Term Debt	0	0	14.78M	152.9M	171.6M	176.2M	191M	214.7M
Capital Lease Obligations	50.35M	0	54.13M	78.1M	0	0	0	0
Deferred Tax Liabilities	-214.03M	-205.65M	0	0	66.7M	6.2M	39.7M	42.4M
Other Non-Current Liabilities	214.03M	0	97.11M	109.8M	208.2M	42.1M	60.7M	155.3M
Total Liabilities	422.92M	385.99M	304.15M	946.8M	3.94B	3.22B	2.76B	3.12B
Total Debt+	50.35M	54.22M	74.21M	240.1M	301.5M	212.2M	219.1M	254.2M
Net Debt	-121.76M	-357.28M	-444.94M	-970.1M	-1.39B	-13.66B	-11.44B	-9.51B
Debt / Equity	-	0.20x	0.15x	0.18x	0.03x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	0.02x	0.02x	0.25x	-
Net Debt / EBITDA	-	-	-	-	-0.09x	-1.07x	-13.10x	-
Interest Coverage	-94.06x	-30.30x	-107.17x	-44.21x	2715.05x	799.08x	88.96x	-99.86x
Total Equity+	-48.21M	267M	493.49M	1.37B	11.89B	20.06B	20.25B	19.41B
Equity Growth %	-	6.54%	0.85%	1.78%	7.67%	0.69%	0.01%	-0.04%
Book Value per Share	-0.21	1.18	2.33	5.52	45.80	80.29	83.42	80.75
Total Shareholders' Equity	-49.3M	266.15M	493.49M	1.37B	11.89B	20.06B	20.25B	19.41B
Common Stock	166.76M	193.3M	232.3M	246.3M	246.3M	248.6M	248.6M	248.6M
Retained Earnings	-197.75M	-245.77M	-424.83M	-409.6M	9.88B	18.83B	19.76B	19.1B
Treasury Stock	0	0	-5.53M	-4.8M	-3.8M	-5.3M	-10.8M	-8.6M
Accumulated OCI	-18.31M	318.63M	691.54M	1.54B	93.9M	-848.9M	-984.6M	-1.33B
Minority Interest	1.09M	847K	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-52.56M	-58.18M	-198.5M	-13.5M	889.7M	13.58B	5.37B	207.7M
Operating CF Margin %	-0.85%	-0.46%	-1.83%	-0.03%	0.05%	0.78%	1.41%	0.08%
Operating CF Growth %	-	-0.11%	-2.41%	0.93%	66.9%	14.26%	-0.6%	-0.96%
Net Income	-85.91M	-47.66M	-179.4M	-145.8M	15.05B	12.95B	1.19B	-677.7M
Depreciation & Amortization	10.53M	21.98M	33.9M	38.7M	75.2M	123.3M	183.4M	298M
Stock-Based Compensation	5.91M	7.64M	30.2M	32.1M	93.9M	108.6M	51.4M	100.9M
Deferred Taxes	26.27M	1.04M	0	0	0	0	0	0
Other Non-Cash Items	-1.4M	-226K	300K	154.6M	-3.6B	-4.13B	-1.62B	-734.1M
Working Capital Changes	-7.96M	-40.96M	-83.5M	-93.1M	-10.73B	4.52B	5.57B	1.22B
Change in Receivables	-2.82M	-18.73M	2.9M	-247.9M	-11.81B	4.37B	5.37B	387.7M
Change in Inventory	-574K	-1.25M	-5.8M	-49.8M	-438.4M	62.9M	81.9M	74.5M
Change in Payables	-4.57M	-20.98M	-80.6M	204.6M	1.52B	85.7M	118.9M	758.4M
Cash from Investing+	-52.55M	-67.15M	-77.2M	-144.8M	-566.1M	-35.3M	-6.95B	-2.08B
Capital Expenditures	-57.74M	-67.85M	-38.6M	-66M	-127.5M	-329.2M	-250.1M	-286.5M
CapEx % of Revenue	0.94%	0.53%	0.36%	0.14%	0.01%	0.02%	0.07%	0.1%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	5.19M	706K	-32.5M	-18.2M	-23.1M	-33.5M	-576.59M	-164.6M
Cash from Financing+	-1.64M	365.18M	383.3M	894.7M	94.2M	-1.42B	-778.6M	-45.9M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	-484.3M	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-110.3M	-126.03M	-269.6M	-98.9M	735.7M	13.21B	4.67B	-244.6M
FCF Margin %	-1.79%	-0.99%	-2.48%	-0.21%	0.04%	0.76%	1.22%	-0.09%
FCF Growth %	-	-0.14%	-1.14%	0.63%	8.44%	16.96%	-0.65%	-1.05%
FCF per Share	-0.49	-0.56	-1.27	-0.40	2.83	52.90	19.22	-1.02
FCF Conversion (FCF/Net Income)	0.61x	1.21x	1.11x	-0.89x	0.09x	1.44x	5.77x	-0.31x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-43.89%	-47.1%	1.63%	155.18%	59.06%	4.62%	-3.36%
Return on Invested Capital (ROIC)	-	-	-280.36%	-27.45%	210.25%	112.25%	6.82%	-10.54%
Gross Margin	84.87%	89.27%	83.98%	87.7%	84.66%	82.7%	84.29%	80.32%
Net Margin	-139.05%	-37.64%	-164.92%	3.15%	54.24%	54.5%	24.36%	-24.18%
Debt / Equity	-	0.20x	0.15x	0.18x	0.03x	0.01x	0.01x	0.01x
Interest Coverage	-94.06x	-30.30x	-107.17x	-44.21x	2715.05x	799.08x	88.96x	-99.86x
FCF Conversion	0.61x	1.21x	1.11x	-0.89x	0.09x	1.44x	5.77x	-0.31x
Revenue Growth	-	107.11%	-14.87%	344.11%	3834.63%	-8.78%	-77.94%	-27.96%

Revenue by Segment

	2019	2020	2021	2022	2023	2024
Other Sales	-	-	-	-	-	319M
Other Sales Growth	-	-	-	-	-	-
Commercial	-	-	71.38B	-	3.82B	-
Commercial Growth	-	-	-	-	-	-
Research And Development	-	-	205.4M	116M	3.5M	-
Research And Development Growth	-	-	-	-43.52%	-96.98%	-
Other Sales Transactions	-	33M	-	-	-	-
Other Sales Transactions Growth	-	-	-	-	-	-
Collaboration Agreement	4.23M	-	-	-	-	-
Collaboration Agreement Growth	-	-	-	-	-	-
Bill And Hold Transaction	1.06M	-	-	-	-	-
Bill And Hold Transaction Growth	-	-	-	-	-	-

Revenue by Geography

	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	14.64B	12.71B	3.01B	1.85B
UNITED STATES Growth	-	-	-	-13.16%	-76.31%	-38.63%
GERMANY	-	20.6M	2.24B	-	482.7M	706.9M
GERMANY Growth	-	-	10783.01%	-	-	46.45%
the World	-	-	-	-	-	196.4M
the World Growth	-	-	-	-	-	-
DELAWARE	-	-	-	3.03B	-	-
DELAWARE Growth	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

BioNTech SE (BNTX) reported $3.15B in revenue for fiscal year 2024. This represents a 5018% increase from $61.6M in 2017.

BioNTech SE (BNTX) saw revenue decline by 28.0% over the past year.

BioNTech SE (BNTX) reported a net loss of $571.6M for fiscal year 2024.

Dividend & Returns

BioNTech SE (BNTX) has a return on equity (ROE) of -3.4%. Negative ROE indicates the company is unprofitable.

BioNTech SE (BNTX) had negative free cash flow of $562.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

BioNTech SE (BNTX) 10-Year Financial Performance & Capital Metrics

BNTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $2.75B -28.0%
EBITDA -$1.02B -216.3%
Net Income -$665M -171.5%
EPS (Diluted) -2.77 -172.3%
Gross Margin 80.32% -4.7%
EBITDA Margin -36.94% -261.5%
Operating Margin -47.77% -364.3%
Net Margin -24.18% -199.3%
ROE -3.36% -172.7%
ROIC -10.54% -254.6%
Debt/Equity 0.01 +21.0%
Interest Coverage -99.86 -212.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Excellent 3Y average ROE of 20.1%
✓Strong 5Y sales CAGR of 90.9%
✓Healthy 5Y average net margin of 22.4%
✓Trading at only 1.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y90.87%

3Y-47.47%

TTM3.7%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-22.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM-13.94%

ROCE

10Y Avg26.41%

5Y Avg56.95%

3Y Avg24.77%

Latest-6.42%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	61.6M	127.58M	108.6M	482.3M	18.98B	17.31B	3.82B	2.75B
Revenue Growth %	-	1.07%	-0.15%	3.44%	38.35%	-0.09%	-0.78%	-0.28%
Cost of Goods Sold+	9.32M	13.69M	17.4M	59.3M	2.91B	3B	599.8M	541.3M
COGS % of Revenue	0.15%	0.11%	0.16%	0.12%	0.15%	0.17%	0.16%	0.2%
Gross Profit+	52.28M	113.89M	91.2M	423M	16.07B	14.32B	3.22B	2.21B
Gross Margin %	0.85%	0.89%	0.84%	0.88%	0.85%	0.83%	0.84%	0.8%
Gross Profit Growth %	-	1.18%	-0.2%	3.64%	36.98%	-0.11%	-0.78%	-0.31%
Operating Expenses+	113.56M	167.74M	272.7M	505.4M	781.4M	1.67B	2.53B	3.52B
OpEx % of Revenue	1.84%	1.31%	2.51%	1.05%	0.04%	0.1%	0.66%	1.28%
Selling, General & Admin	29.49M	27.07M	43.3M	108.5M	327.2M	541.2M	557.7M	599M
SG&A % of Revenue	0.48%	0.21%	0.4%	0.22%	0.02%	0.03%	0.15%	0.22%
Research & Development	85.5M	143.07M	226.5M	645M	949.2M	1.54B	1.78B	2.25B
R&D % of Revenue	1.39%	1.12%	2.09%	1.34%	0.05%	0.09%	0.47%	0.82%
Other Operating Expenses	-1.43M	-2.39M	2.9M	-248.1M	-495M	-405.3M	188M	670.9M
Operating Income+	-61.28M	-53.85M	-181.5M	-82.4M	15.28B	12.64B	690.4M	-1.31B
Operating Margin %	-0.99%	-0.42%	-1.67%	-0.17%	0.81%	0.73%	0.18%	-0.48%
Operating Income Growth %	-	0.12%	-2.37%	0.55%	186.48%	-0.17%	-0.95%	-2.9%
EBITDA+	-50.75M	-31.87M	-147.6M	-43.7M	15.36B	12.77B	873.8M	-1.02B
EBITDA Margin %	-0.82%	-0.25%	-1.36%	-0.09%	0.81%	0.74%	0.23%	-0.37%
EBITDA Growth %	-	0.37%	-3.63%	0.7%	352.46%	-0.17%	-0.93%	-2.16%
D&A (Non-Cash Add-back)	10.53M	21.98M	33.9M	38.7M	75.2M	123.3M	183.4M	298M
EBIT	-85.23M	-45.94M	-177.7M	-143.8M	14.93B	12.97B	1.19B	-665.1M
Net Interest Income+	1.4M	284.04K	62.1K	-408.5K	-4.07M	31.55M	343.55M	-13.16M
Interest Income	2.06M	2.06M	1.76M	1.46M	1.56M	47.37M	351.31M	0
Interest Expense	651.44K	1.78M	1.69M	1.86M	5.63M	15.82M	7.76M	13.16M
Other Income/Expense	-24.63M	6.19M	2.1M	-63.4M	-237.4M	311.4M	495.7M	636.6M
Pretax Income+	-85.91M	-47.66M	-179.4M	-145.8M	15.05B	12.95B	1.19B	-677.7M
Pretax Margin %	-1.39%	-0.37%	-1.65%	-0.3%	0.79%	0.75%	0.31%	-0.25%
Income Tax+	45K	600K	-200K	-161M	4.75B	3.52B	255.8M	-12.4M
Effective Tax Rate %	1%	1.01%	1%	-0.1%	0.68%	0.73%	0.78%	0.98%
Net Income+	-85.65M	-48.02M	-179.1M	15.2M	10.29B	9.43B	930.3M	-665.3M
Net Margin %	-1.39%	-0.38%	-1.65%	0.03%	0.54%	0.55%	0.24%	-0.24%
Net Income Growth %	-	0.44%	-2.73%	1.08%	676.14%	-0.08%	-0.9%	-1.72%
Net Income (Continuing)	-85.95M	-48.26M	-179.2M	15.2M	10.29B	9.43B	930.3M	-665.3M
Discontinued Operations	91.29K	0	0	0	0	0	0	0
Minority Interest	1.09M	847K	0	0	0	0	0	0
EPS (Diluted)+	-0.38	-0.21	-0.85	0.06	41.21	37.09	3.83	-2.77
EPS Growth %	-	0.45%	-3.05%	1.07%	721.98%	-0.1%	-0.9%	-1.72%
EPS (Basic)	-0.38	-0.21	-0.85	0.06	43.87	38.08	3.87	-2.77
Diluted Shares Outstanding	226.86M	226.86M	211.5M	248.53M	259.7M	249.8M	242.7M	240.4M
Basic Shares Outstanding	226.86M	226.86M	211.5M	235.44M	244M	243.3M	240.6M	240.4M
Dividend Payout Ratio	-	-	-	-	-	0.05%	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	189.64M	448.96M	560.15M	1.67B	15.07B	21.92B	19.53B	18.8B
Cash & Short-Term Investments	172.35M	411.83M	520.83M	1.35B	2.07B	14.06B	16.55B	16.78B
Cash Only	172.11M	411.5M	519.15M	1.21B	1.69B	13.88B	11.66B	9.76B
Short-Term Investments	246K	336K	1.68M	137.2M	381.6M	189.4M	4.89B	7.02B
Accounts Receivable	4.58M	28.44M	11.91M	165.5M	12.38B	7.15B	2.34B	1.52B
Days Sales Outstanding	27.11	81.37	40.04	125.25	238.16	150.68	223.62	202.18
Inventory	3.88M	5.79M	12.07M	64.1M	502.5M	439.6M	357.7M	283.3M
Days Inventory Outstanding	151.83	154.35	253.26	394.54	63	53.57	217.67	191.03
Other Current Assets	8.83M	12.25M	15.34M	89.9M	113.4M	271.9M	280.9M	212.7M
Total Non-Current Assets+	185.08M	204.03M	237.5M	651.7M	758.5M	1.36B	3.48B	3.73B
Property, Plant & Equipment	101.52M	115.97M	148.06M	326M	520.4M	821.1M	971.6M	1.18B
Fixed Asset Turnover	0.61x	1.10x	0.73x	1.48x	36.47x	21.08x	3.93x	2.32x
Goodwill	534K	534K	2.98M	53.7M	57.8M	61.2M	362.5M	380.6M
Intangible Assets	83M	87.51M	84.05M	103.8M	144.6M	158.5M	804.1M	790.4M
Long-Term Investments	19K	18K	0	0	21.3M	80.2M	1.18B	1.25B
Other Non-Current Assets	-2K	-1K	2.4M	168.2M	14.4M	6.5M	83.4M	36.1M
Total Assets+	374.71M	652.99M	797.65M	2.32B	15.83B	23.28B	23.01B	22.53B
Asset Turnover	0.16x	0.20x	0.14x	0.21x	1.20x	0.74x	0.17x	0.12x
Asset Growth %	-	0.74%	0.22%	1.91%	5.83%	0.47%	-0.01%	-0.02%
Total Current Liabilities+	158.54M	126.12M	138.14M	606M	3.48B	2.95B	2.07B	2.52B
Accounts Payable	52.54M	41.72M	20.5M	102.3M	160M	204.1M	354M	426.7M
Days Payables Outstanding	2.06K	1.11K	429.99	629.67	20.06	24.87	215.42	287.72
Short-Term Debt	0	0	1.82M	3M	129.9M	36M	28.1M	39.5M
Deferred Revenue (Current)	1000K	1000K	0	0	1000K	1000K	1000K	1000K
Other Current Liabilities	86.73M	79.16M	105.63M	494.6M	1.44B	2.04B	809.6M	1.76B
Current Ratio	1.20x	3.56x	4.05x	2.75x	4.33x	7.43x	9.43x	7.45x
Quick Ratio	1.17x	3.51x	3.97x	2.64x	4.18x	7.28x	9.26x	7.34x
Cash Conversion Cycle	-1.88K	-876.64	-136.69	-109.88	281.1	179.38	225.87	105.49
Total Non-Current Liabilities+	264.38M	259.87M	166.01M	340.8M	455.5M	272.9M	689.9M	595.4M
Long-Term Debt	0	0	14.78M	152.9M	171.6M	176.2M	191M	214.7M
Capital Lease Obligations	50.35M	0	54.13M	78.1M	0	0	0	0
Deferred Tax Liabilities	-214.03M	-205.65M	0	0	66.7M	6.2M	39.7M	42.4M
Other Non-Current Liabilities	214.03M	0	97.11M	109.8M	208.2M	42.1M	60.7M	155.3M
Total Liabilities	422.92M	385.99M	304.15M	946.8M	3.94B	3.22B	2.76B	3.12B
Total Debt+	50.35M	54.22M	74.21M	240.1M	301.5M	212.2M	219.1M	254.2M
Net Debt	-121.76M	-357.28M	-444.94M	-970.1M	-1.39B	-13.66B	-11.44B	-9.51B
Debt / Equity	-	0.20x	0.15x	0.18x	0.03x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	0.02x	0.02x	0.25x	-
Net Debt / EBITDA	-	-	-	-	-0.09x	-1.07x	-13.10x	-
Interest Coverage	-94.06x	-30.30x	-107.17x	-44.21x	2715.05x	799.08x	88.96x	-99.86x
Total Equity+	-48.21M	267M	493.49M	1.37B	11.89B	20.06B	20.25B	19.41B
Equity Growth %	-	6.54%	0.85%	1.78%	7.67%	0.69%	0.01%	-0.04%
Book Value per Share	-0.21	1.18	2.33	5.52	45.80	80.29	83.42	80.75
Total Shareholders' Equity	-49.3M	266.15M	493.49M	1.37B	11.89B	20.06B	20.25B	19.41B
Common Stock	166.76M	193.3M	232.3M	246.3M	246.3M	248.6M	248.6M	248.6M
Retained Earnings	-197.75M	-245.77M	-424.83M	-409.6M	9.88B	18.83B	19.76B	19.1B
Treasury Stock	0	0	-5.53M	-4.8M	-3.8M	-5.3M	-10.8M	-8.6M
Accumulated OCI	-18.31M	318.63M	691.54M	1.54B	93.9M	-848.9M	-984.6M	-1.33B
Minority Interest	1.09M	847K	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-52.56M	-58.18M	-198.5M	-13.5M	889.7M	13.58B	5.37B	207.7M
Operating CF Margin %	-0.85%	-0.46%	-1.83%	-0.03%	0.05%	0.78%	1.41%	0.08%
Operating CF Growth %	-	-0.11%	-2.41%	0.93%	66.9%	14.26%	-0.6%	-0.96%
Net Income	-85.91M	-47.66M	-179.4M	-145.8M	15.05B	12.95B	1.19B	-677.7M
Depreciation & Amortization	10.53M	21.98M	33.9M	38.7M	75.2M	123.3M	183.4M	298M
Stock-Based Compensation	5.91M	7.64M	30.2M	32.1M	93.9M	108.6M	51.4M	100.9M
Deferred Taxes	26.27M	1.04M	0	0	0	0	0	0
Other Non-Cash Items	-1.4M	-226K	300K	154.6M	-3.6B	-4.13B	-1.62B	-734.1M
Working Capital Changes	-7.96M	-40.96M	-83.5M	-93.1M	-10.73B	4.52B	5.57B	1.22B
Change in Receivables	-2.82M	-18.73M	2.9M	-247.9M	-11.81B	4.37B	5.37B	387.7M
Change in Inventory	-574K	-1.25M	-5.8M	-49.8M	-438.4M	62.9M	81.9M	74.5M
Change in Payables	-4.57M	-20.98M	-80.6M	204.6M	1.52B	85.7M	118.9M	758.4M
Cash from Investing+	-52.55M	-67.15M	-77.2M	-144.8M	-566.1M	-35.3M	-6.95B	-2.08B
Capital Expenditures	-57.74M	-67.85M	-38.6M	-66M	-127.5M	-329.2M	-250.1M	-286.5M
CapEx % of Revenue	0.94%	0.53%	0.36%	0.14%	0.01%	0.02%	0.07%	0.1%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	5.19M	706K	-32.5M	-18.2M	-23.1M	-33.5M	-576.59M	-164.6M
Cash from Financing+	-1.64M	365.18M	383.3M	894.7M	94.2M	-1.42B	-778.6M	-45.9M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	-484.3M	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-110.3M	-126.03M	-269.6M	-98.9M	735.7M	13.21B	4.67B	-244.6M
FCF Margin %	-1.79%	-0.99%	-2.48%	-0.21%	0.04%	0.76%	1.22%	-0.09%
FCF Growth %	-	-0.14%	-1.14%	0.63%	8.44%	16.96%	-0.65%	-1.05%
FCF per Share	-0.49	-0.56	-1.27	-0.40	2.83	52.90	19.22	-1.02
FCF Conversion (FCF/Net Income)	0.61x	1.21x	1.11x	-0.89x	0.09x	1.44x	5.77x	-0.31x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-43.89%	-47.1%	1.63%	155.18%	59.06%	4.62%	-3.36%
Return on Invested Capital (ROIC)	-	-	-280.36%	-27.45%	210.25%	112.25%	6.82%	-10.54%
Gross Margin	84.87%	89.27%	83.98%	87.7%	84.66%	82.7%	84.29%	80.32%
Net Margin	-139.05%	-37.64%	-164.92%	3.15%	54.24%	54.5%	24.36%	-24.18%
Debt / Equity	-	0.20x	0.15x	0.18x	0.03x	0.01x	0.01x	0.01x
Interest Coverage	-94.06x	-30.30x	-107.17x	-44.21x	2715.05x	799.08x	88.96x	-99.86x
FCF Conversion	0.61x	1.21x	1.11x	-0.89x	0.09x	1.44x	5.77x	-0.31x
Revenue Growth	-	107.11%	-14.87%	344.11%	3834.63%	-8.78%	-77.94%	-27.96%

Revenue by Segment

	2019	2020	2021	2022	2023	2024
Other Sales	-	-	-	-	-	319M
Other Sales Growth	-	-	-	-	-	-
Commercial	-	-	71.38B	-	3.82B	-
Commercial Growth	-	-	-	-	-	-
Research And Development	-	-	205.4M	116M	3.5M	-
Research And Development Growth	-	-	-	-43.52%	-96.98%	-
Other Sales Transactions	-	33M	-	-	-	-
Other Sales Transactions Growth	-	-	-	-	-	-
Collaboration Agreement	4.23M	-	-	-	-	-
Collaboration Agreement Growth	-	-	-	-	-	-
Bill And Hold Transaction	1.06M	-	-	-	-	-
Bill And Hold Transaction Growth	-	-	-	-	-	-

Revenue by Geography

	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	14.64B	12.71B	3.01B	1.85B
UNITED STATES Growth	-	-	-	-13.16%	-76.31%	-38.63%
GERMANY	-	20.6M	2.24B	-	482.7M	706.9M
GERMANY Growth	-	-	10783.01%	-	-	46.45%
the World	-	-	-	-	-	196.4M
the World Growth	-	-	-	-	-	-
DELAWARE	-	-	-	3.03B	-	-
DELAWARE Growth	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

BioNTech SE (BNTX) reported $3.15B in revenue for fiscal year 2024. This represents a 5018% increase from $61.6M in 2017.

BioNTech SE (BNTX) saw revenue decline by 28.0% over the past year.

BioNTech SE (BNTX) reported a net loss of $571.6M for fiscal year 2024.

Dividend & Returns

BioNTech SE (BNTX) has a return on equity (ROE) of -3.4%. Negative ROE indicates the company is unprofitable.

BioNTech SE (BNTX) had negative free cash flow of $562.7M in fiscal year 2024, likely due to heavy capital investments.